Literature DB >> 20555265

Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study.

Sefanja Achterberg1, Maarten J M Cramer, L Jaap Kappelle, Gert Jan de Borst, Frank L J Visseren, Yolanda van der Graaf, Ale Algra.   

Abstract

AIMS: Atherosclerosis causes coronary artery disease (CAD), cerebrovascular disease (CVD) or peripheral arterial obstructive disease (PAOD). The risk of new vascular events and mortality is high. Direct comparisons of vascular event rates are scarce. METHODS AND
RESULTS: Vascular risk factors and outcome events of 3563 patients from a university hospital presenting with nondisabling CAD, CVD or PAOD were compared with regression analyses, adjusted for age and sex (median follow-up, 3.9 years). The primary outcome was the composite of myocardial infarction, stroke and vascular death. The risk among the three groups of outcomes was compared using the Cox regression analysis. At baseline, CAD patients were the most obese; PAOD patients smoked the most and suffered more often from hypertension and hyperlipidaemia. The average rate of vascular events was 2.5% per year; the hazard ratio (HR) of CVD/CAD was 1.7 [95% confidence interval (CI): 1.3-2.2] and PAOD/CAD was 1.8 (95% CI: 1.5-2.0). PAOD patients had a higher risk for coronary events than CAD (HR: 1.6; 95% CI: 1.2-2.1). Patients with CVD or PAOD had a higher risk for major bleeding than CAD patients (HR: 2.1; 95% CI: 1.4-3.2).
CONCLUSION: Patients with a recent CVD or PAOD have almost twice the risk for future vascular events than those with CAD.

Entities:  

Mesh:

Year:  2010        PMID: 20555265     DOI: 10.1097/HJR.0b013e3283361ce6

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  8 in total

Review 1.  The pharmacology of novel oral anticoagulants.

Authors:  Tracy A DeWald; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  Prospective intraindividual comparison of gadoterate and gadobutrol for cervical and intracranial contrast-enhanced magnetic resonance angiography.

Authors:  Philip Hoelter; Stefan Lang; Marina Weibart; Manuel Schmidt; Michael F X Knott; Tobias Engelhorn; Marco Essig; Stephan Kloska; Arnd Doerfler
Journal:  Neuroradiology       Date:  2017-09-14       Impact factor: 2.804

3.  Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.

Authors:  Saskia H Meves; Thomas Hummel; Heinz G Endres; Nora Mayböck; Andreas F C Kaiser; Kay D Schröder; Katja Rüdiger; Ursula Overbeck; Achim Mumme; Andreas Mügge; Horst Neubauer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

4.  Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomics.

Authors:  Alicia Lundby; Elizabeth J Rossin; Annette B Steffensen; Moshe Rav Acha; Christopher Newton-Cheh; Arne Pfeufer; Stacey N Lynch; Søren-Peter Olesen; Søren Brunak; Patrick T Ellinor; J Wouter Jukema; Stella Trompet; Ian Ford; Peter W Macfarlane; Bouwe P Krijthe; Albert Hofman; André G Uitterlinden; Bruno H Stricker; Hendrik M Nathoe; Wilko Spiering; Mark J Daly; Folkert W Asselbergs; Pim van der Harst; David J Milan; Paul I W de Bakker; Kasper Lage; Jesper V Olsen
Journal:  Nat Methods       Date:  2014-06-22       Impact factor: 28.547

5.  The occurrence of seizures after ischemic stroke does not influence long-term mortality; a 26-year follow-up study.

Authors:  J H van Tuijl; E P M van Raak; R J van Oostenbrugge; A P Aldenkamp; R P W Rouhl
Journal:  J Neurol       Date:  2018-05-29       Impact factor: 4.849

6.  The impact of left ventricular diastolic dysfunction for the prognosis in patients with lower extremity arterial disease.

Authors:  Jen-Kuang Lee; Juey-Jen Hwang; Fu-Tien Chiang; Cho-Kai Wu
Journal:  ESC Heart Fail       Date:  2020-06-24

7.  Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease.

Authors:  Rutao Wang; Scot Garg; Chao Gao; Hideyuki Kawashima; Masafumi Ono; Hironori Hara; Robert-Jan van Geuns; Marie-Claude Morice; Piroze M Davierwala; Arie Pieter Kappetein; David R Holmes; William Wijns; Ling Tao; Yoshinobu Onuma; Patrick W Serruys
Journal:  Clin Res Cardiol       Date:  2021-08-25       Impact factor: 5.460

8.  Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.

Authors:  Monica Bocchia; Sara Galimberti; Lara Aprile; Anna Sicuranza; Antonella Gozzini; Francesca Santilli; Elisabetta Abruzzese; Claudia Baratè; Barbara Scappini; Giulia Fontanelli; Monika Malgorzata Trawinska; Marzia Defina; Alessandro Gozzetti; Alberto Bosi; Mario Petrini; Luca Puccetti
Journal:  Oncotarget       Date:  2016-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.